CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands	9 Months Ended
	Sep. 30, 2011	Sep. 30, 2010
Net cash used in operating activities	$ (90,467)	$ (38,090)
Investing activities:
Purchases of short-term investments	(284,379)	(429,631)
Proceeds from the sale of short-term investments	371,872	483,476
Purchases of property, plant and equipment	(7,655)	(12,740)
Proceeds from land sold to BioMed		10,147
Reduction of cash due to deconsolidation of Regulus Therapeutics Inc. upon adoption of a new accounting standard		(16,228)
Acquisition of licenses and other assets	(2,544)	(3,430)
Purchases of strategic investments	(359)	(658)
Net cash provided by investing activities	76,935	30,936
Financing activities:
Proceeds from issuance of equity	1,554	2,036
Proceeds from equipment financing arrangement	1,625	3,083
Principal payments on debt and capital lease obligations	(4,436)	(3,098)
Net cash (used in) provided by financing activities	(1,257)	2,021
Net decrease in cash and cash equivalents	(14,789)	(5,133)
Cash and cash equivalents at beginning of period	70,052	105,255
Cash and cash equivalents at end of period	55,263	100,122
Supplemental disclosures of cash flow information:
Interest paid	4,647	4,694
Income taxes paid	2	7,700
Supplemental disclosures of non-cash investing and financing activities:
Amounts accrued for capital and patent expenditures	1,378	927
Capitalized costs and financing liability associated with leased facility	$ 58,748